Flex Pharma, Inc. (FLKS) financial statements (2020 and earlier)

Company profile

Business Address 2450 HOLCOMBE BLVD
HOUSTON, TX 77021
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41033619134
Cash and cash equivalents41019226734
Short-term investments  143925 
Restricted cash and investments 0    
Receivables 000  
Inventory, net of allowances, customer advances and progress billings 000  
Inventory 000  
Prepaid expense1     
Deferred costs     1
Other current assets0     
Other undisclosed current assets00111(1)
Total current assets:51035629234
Noncurrent Assets
Property, plant and equipment000100
Long-term investments and receivables    2 
Long-term investments    2 
Intangible assets, net (including goodwill)9     
Goodwill9     
Restricted cash and investments  0000
Deferred costs     1
Other noncurrent assets0  0 0
Other undisclosed noncurrent assets     0
Total noncurrent assets:900131
TOTAL ASSETS:141035639536
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities213331
Accounts payable202111
Accrued liabilities 00000
Employee-related liabilities 01110
Deferred revenue2
Debt1     
Derivative instruments and hedges, liabilities0     
Restructuring reserve 0    
Due to related parties0     
Deferred revenue and credits0000
Deferred tax liabilities    0
Other undisclosed current liabilities 03100
Total current liabilities:416431
Noncurrent Liabilities
Liabilities, other than long-term debt  0000
Deferred revenue and credits0000
Other liabilities    00
Total noncurrent liabilities:  0000
Other undisclosed liabilities0     
Total liabilities:516431
Stockholders' equity
Stockholders' equity attributable to parent109295992(7)
Common stock000000
Additional paid in capital201421401361291
Accumulated other comprehensive loss  (0)(0)(0) 
Accumulated deficit(10)(133)(111)(77)(37)(8)
Other undisclosed stockholders' equity     41
Total stockholders' equity:10929599234
TOTAL LIABILITIES AND EQUITY:141035639536

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues11110 
Revenue, net11  
Net investment income00 00 
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(0)  
Gross profit:10110 
Operating expenses(11)(23)(36)(41)(29) 
Other undisclosed operating income0000  
Operating loss:(9)(22)(35)(40)(29) 
Nonoperating expense
(Investment Income, Nonoperating)
    (0) 
Loss from continuing operations before equity method investments, income taxes:(9)(22)(35)(40)(29) 
Other undisclosed loss from continuing operations before income taxes    (0) 
Net loss:(9)(22)(35)(40)(29) 
Other undisclosed net income attributable to parent10000 
Net loss available to common stockholders, diluted:(8)(22)(34)(39)(29) 

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(9)(22)(35)(40)(29) 
Other comprehensive income (loss)   0(0) 
Comprehensive loss:(9)(22)(35)(40)(29) 
Other undisclosed comprehensive income, net of tax, attributable to parent00000 
Comprehensive loss, net of tax, attributable to parent:(9)(22)(34)(39)(29) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: